Navigation Links
Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008

SOUTH EASTON, Mass., March 4 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI" or the "Company") today announced that total revenue for the fourth quarter of 2008 was $334,041 compared to $174,071 for the comparable period in 2007, a 92% increase. Revenue from the sale of PCT products and services was $233,256 for the three months ended December 31, 2008 compared to $118,703 for the same period in 2007, a 97% increase. During the fourth quarter of 2008, the Company completed the installation of ten Barocycler instruments, as compared to seven during the same period of 2007. Eight of the ten were domestic installations and two were international sales, compared to three domestic installations and four international sales for the same quarter in 2007.

Operating loss for the fourth quarter of 2008 was $900,100 compared to $1,297,975 for the same period in 2007, a decrease of $(397,875) or 30%. This decrease in operating loss was primarily related to the Company's restructuring program announced on December 1, 2008, the cost containment initiatives that the Company instituted during the second and third quarters of 2008, and the record revenues of the 2008 fourth quarter. The Company currently expects its operating loss to continue to decrease to an average of less than $600,000 per quarter during 2009.

As the Company is completing its annual financial reporting and auditing process, the revenue and operating numbers mentioned in this release are unaudited.

Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc. said: "The fourth quarter of 2008 was extremely difficult for PBI. Faced with a very tough economic climate and decreasing cash, we made the difficult decision to significantly restructure the Company. Changes related to the restructuring program included a reduction in force from twenty to twelve employees, the implementation of significant cost reduction initiatives, and a realignment of our corporate strategy to focus on key products and application areas with the greatest likelihood for success."

Mr. Schumacher continued: "Amidst the upheaval and uncertainty resulting from these changes, we were still able to complete a license agreement with Battelle Memorial Institute; enter into a collaboration agreement with the J. Craig Venter Institute; sign an initial distribution agreement with Omni International; make significant progress towards the planned Q3 2009 release of our PCT-enhanced Protein Digestion System, including the next generation small and variable volume consumable processing containers; release a new product called the PCT Shredder; and make measurable progress on our equity financing efforts (completed on February 12, 2009). Concomitantly, we were also able to achieve record revenue while significantly reducing our operating loss. All stakeholders of the Company should be extremely proud of the team that we have at PBI, just as I am."

As previously announced, the Company completed a $1.8 million equity financing on February 12, 2009. In connection with the financing, investors purchased units, with each unit consisting of (i) one share of Series A Convertible Preferred Stock (the "Series A Preferred Stock"), (ii) a warrant to purchase 10 shares of Common Stock at an exercise price equal to $2.00 per share with a term expiring 30 months after the date of the closing of the financing, and (iii) a warrant to purchase, at the investor's election to be made within 7 days of the closing, either 10 shares of Common Stock at an exercise price equal to $1.25 per share with a term expiring 15 months after the closing (the "15-Month Common Stock Warrants") or one share of Series A Preferred Stock at an exercise price equal to $12.50 per share with a term expiring 15 months after the closing (the "15-Month Preferred Stock Warrants"). All 35 investors elected the 15-Month Preferred Stock Warrants. Since the Company had agreed to register the shares of Common Stock underlying the 15-Month Common Stock Warrants, as a result of the investors' elections, the Company will not be registering shares of Common Stock underlying the 15-Month Common Stock Warrants.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical (primarily enzymatic) reactions, immunodiagnostics, and protein purification. PBI currently focuses its efforts in the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, and counter-bioterror applications.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include statements regarding the sufficiency of the Company's cash resources to fund its planned operations through the second quarter of 2010, the Company's expectation that it's operating loss will continue to decrease to an average of less than $600,000 per quarter in 2009, the Company's ability to achieve its business goals, the effect of the Company's decision to focus primarily on the application of PCT-enhanced protein digestion for the mass spectrometry market and the advantages of PCT in this market, and the use of PCT in biomarker discovery, soil and plant biology, counter-bioterror, and tissue pathology applications. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of its PCT System; changes in customer's needs and technological innovations; the Company's sales force may not be successful in selling the Company's PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods, particularly in the mass spectrometry market; scientists may not be able to duplicate the results achieved at particular laboratories having already used PCT; and if actual operating costs are higher than anticipated, or revenues from product sales are less than anticipated, the Company will need additional capital sooner than the second quarter of 2010. Further, the Company expects that it will need additional capital to fund its continuing operations beyond the second quarter of 2010. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website

    Investor Contacts:
    Richard T. Schumacher, President & CEO
    R. Wayne Fritzsche, Chairman
    Pressure BioSciences, Inc.
    (508) 230-1828 (T)

    Consolidated Balance Sheets
                                                            December 31,
                          ASSETS                          2008        2007
                          ------                          ----        ----

      Cash and cash equivalents                       $918,208  $5,424,486
      Accounts receivable                              209,117     118,471
      Inventories                                      571,831     172,548
      Deposits                                         382,236     553,483
      Prepaid income taxes                               6,600      56,863
      Income tax receivable                                  -     249,541
      Prepaid expenses and other current assets        235,111      94,783
                                                       -------      ------
      Total current assets                           2,323,103   6,670,175
                                                     ---------   ---------

    PROPERTY AND EQUIPMENT, NET                        252,249     257,797
                                                       -------     -------

      Intangible assets, net                           279,658     328,290
                                                       -------     -------
      TOTAL ASSETS                                  $2,855,010  $7,256,262
                                                    ==========  ==========


      Accounts payable                                $263,486    $152,729
      Accrued employee compensation                    161,374     377,190
      Accrued professional fees and other expenses     278,982     191,359
      Deferred revenue                                  16,705      15,075
                                                        ------      ------
      Total current liabilities                        720,547     736,353
                                                       -------     -------

      Deferred revenue                                  10,821       6,767
                                                        ------       -----
      TOTAL LIABILITIES                                731,368     743,120
                                                       -------     -------


      Preferred stock; 1,000,000 shares
       authorized; 0 outstanding                             -           -
      Common stock, $.01 par value; 20,000,000
       shares authorized; 2,195,283 shares issued
       and outstanding on December 31, 2008 and
       2,192,175 shares issued and outstanding on
       December 31, 2007                                21,953      21,922
      Additional paid-in capital                     6,803,530   6,284,616
      Retained (deficit) earnings                   (4,701,841)    206,604
                                                    ----------     -------
      Total stockholders' equity                     2,123,642   6,513,142
                                                     ---------   ---------
      TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY    $2,855,010  $7,256,262
                                                    ==========  ==========

    Consolidated Statements of Operations
                                                For the Three Months
                                                    December 31,
                                                  2008        2007
                                                  ----        ----

      PCT Products, services, other             $233,256    $118,703
      Grant revenue                              100,785      55,368
                                                 -------      ------
        Total revenue                            334,041     174,071
                                                 -------     -------

      Cost of PCT products and services          133,601      77,492
      Research and development                   481,435     503,879
      Selling and marketing                      302,443     399,718
      General and administrative                 316,662     490,957
                                                 -------     -------
        Total operating costs and expenses     1,234,141   1,472,046
                                               ---------   ---------

        Operating loss                          (900,100) (1,297,975)

      Interest income                              1,616      58,784
                                                   -----      ------
        Total other income                         1,616      58,784

        Loss before income taxes                (898,484) (1,239,191)
        Income tax benefit                             -     266,675
                                                 -------     -------
        Net loss                               $(898,484)  $(972,516)
                                               =========   =========

      Loss per share - basic and diluted          $(0.41)     $(0.46)

      Weighted average number of shares used
       to calculate net loss per share - basic
       and diluted                             2,195,283   2,118,354

SOURCE Pressure BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
2. Pressure BioSciences, Inc. Issued First Patent in Canada
3. Interventional Cardiologists Nico Pijls, Bernard De Bruyne to Discuss Benefits of Measuring Coronary Pressure in Improving Multivessel PCI at ESC Congress 2007
4. Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320
5. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
6. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
7. Pressure BioSciences, Inc. Provides Corporate Update
8. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
9. The sensitive side of carbon nanotubes: Creating powerful pressure sensors
10. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
11. Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
Post Your Comments:
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... ... 10, 2017 , ... Dr. Bob Harman, founder and CEO of VetStem ... The event entitled “Stem Cells and Their Regenerative Powers,” was held ... Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
(Date:10/10/2017)... PITTSBURGH, PA (PRWEB) , ... October 10, 2017 ... ... this year’s recipients of 13 prestigious awards honoring scientists who ... be presented in a scheduled symposium during Pittcon 2018, the world’s leading conference ...
Breaking Biology Technology:
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
Breaking Biology News(10 mins):